Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders. Learn ...
WOMEN can wait up to 16 years to be diagnosed with a life-threatening condition dismissed as heavy periods. By contrast, it ...
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026 ...
Routine dental procedures can be dangerous for haemophilia patients without proper planning. A review urges preventive care, ...
A new report in The Lancet Haematology, led by Cleveland Clinic hematologist Bethany Samuelson Bannow, M.D., outlines ...
Incyte Corporation (NASDAQ:INCY) on Monday reported complete Phase 1/2 multidose data for latarcibart (VGA039), showing ...
Spark Biomedical today announced publication of a first-in-human study with Northwell Health's Feinstein Institutes for Medical Research. The study, published in Bioelectronic Medicine, shows Spark's ...
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, ...
Kingdom of Earth #1 from Dark Horse Comics arrives Wednesday, July 15th, priced at $4.99, featuring humanity as livestock in ...
Explore the complex link between autoimmune diseases and blood cancers, emphasizing early detection and recognition of ...
Abnormal period blood - in color, volume, or timing - can signal fibroids, adenomyosis, bleeding disorders, or infection. The ...
Zyryenj "Gft" S. Agoncillo says he is a testament that a person with a bleeding disorder can live a meaningful life and raise ...